Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)– The U.S. Food and Drug Administration (FDA) approved ZINBRYTA TM (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for...